Cite
Psichogiou M, Karabinis A, Poulakou G, et al. Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines (Basel). 2021;9(9)doi: 10.3390/vaccines9091017.
Psichogiou, M., Karabinis, A., Poulakou, G., Antoniadou, A., Kotanidou, A., Degiannis, D., Pavlopoulou, I. D., Chaidaroglou, A., Roussos, S., Mastrogianni, E., Eliadi, I., Basoulis, D., Petsios, K., Leontis, K., Kakalou, E., Protopapas, K., Jahaj, E., Pratikaki, M., Syrigos, K. N., Lagiou, P., Gogas, H., Tsiodras, S., Magiorkinis, G., Paraskevis, D., Sypsa, V., & Hatzakis, A. (2021). Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines, 9(9), . https://doi.org/10.3390/vaccines9091017
Psichogiou, Mina, et al. "Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection." Vaccines vol. 9,9 (2021). doi: https://doi.org/10.3390/vaccines9091017
Psichogiou M, Karabinis A, Poulakou G, Antoniadou A, Kotanidou A, Degiannis D, Pavlopoulou ID, Chaidaroglou A, Roussos S, Mastrogianni E, Eliadi I, Basoulis D, Petsios K, Leontis K, Kakalou E, Protopapas K, Jahaj E, Pratikaki M, Syrigos KN, Lagiou P, Gogas H, Tsiodras S, Magiorkinis G, Paraskevis D, Sypsa V, Hatzakis A. Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. Vaccines (Basel). 2021 Sep 13;9(9). doi: 10.3390/vaccines9091017. PMID: 34579254; PMCID: PMC8471735.
Copy
Download .nbib